Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. reported second-quarter 2026 revenue of $2,468 million, essentially flat versus the prior year and down 1% on an organic operational basis. Net income was $691 million, or $1.65 per diluted share, down 5% and up 1%, respectively, on a reported basis. Adjusted net income was $781 million and adjusted diluted EPS $1.87, down 1% and up 5% on a reported basis and down 2% and up 4% on an organic operational basis.
U.S. revenue fell 7% to $1,266 million, with companion animal sales down 11% amid softer clinic demand, price sensitivity and generic competition, partly offset by 23% growth in U.S. livestock. International revenue rose 8% to $1,173 million, driven by parasiticides, diagnostics and new osteoarthritis monoclonal antibody launches.
Zoetis updated its 2026 outlook, now guiding to revenue of $9.120–$9.320 billion (organic operational revenue growth of (3)% to (1)%), reported net income of $2.330–$2.380 billion, adjusted net income of $2.570–$2.620 billion (organic operational growth of (9)% to (5)%), reported diluted EPS of $5.55–$5.65 and adjusted diluted EPS of $6.15–$6.25, compared with prior adjusted EPS guidance of $6.85–$7.00.
BlackRock, Inc. reports beneficial ownership of Class A stock of Zoetis Inc. on a Schedule 13G/A. As of 06/30/2026, BlackRock and certain reporting business units beneficially owned 37,660,315 Zoetis Class A shares, representing 9.0% of the class.
BlackRock had sole voting power over 34,828,271 shares and sole dispositive power over all 37,660,315 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Zoetis’s outstanding common shares.
Sarbaugh Keith reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Keith Sarbaugh received a grant of 259.6384 phantom stock units on July 10, 2026 under the Zoetis Supplemental Savings Plan. These cash-settled units track the value of Zoetis common stock and increase his total phantom stock holdings to 2364.8311 units.
PECK KRISTIN C reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Chief Executive Officer Kristin C. Peck reported a grant of 616.0892 phantom stock units on 2026-07-10 under the Zoetis Supplemental Savings Plan at $26.2200 per unit. Each unit’s value tracks Zoetis common stock plus cash-equivalent investments and is settled in cash, bringing her balance to 66,194.8959 phantom units.
Nayak Abhay U reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Abhay U. Nayak received a compensation-related grant of 214.6155 Phantom Stock Units on 2026-07-10 under the Zoetis Supplemental Savings Plan. These cash-settled units track Zoetis common stock plus cash-equivalent investments and increase his phantom stock balance to 4,700.5887 units.
Esch Kevin reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Kevin Esch received a grant of 308.0457 phantom stock units on July 10, 2026 under the Zoetis Supplemental Savings Plan at a reference value of $26.2200 per unit. These cash-settled units track the value of Zoetis common stock plus a small cash-equivalent component, and Esch now holds 806.4312 phantom stock units in total, representing an interest tied to 106.8946 underlying shares of Zoetis common stock.
Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Rimma Driscoll received a grant of 237.6361 phantom stock units on July 10, 2026 at a reference value of $26.2200 per unit under the Zoetis Supplemental Savings Plan, bringing her total phantom stock unit balance to 6,273.3823 units, economically corresponding to 82.4619 phantom common stock equivalents.
These phantom stock units are settled in cash after her separation from service and may be reallocated among investment funds, with Zoetis able to limit transfer timing and frequency; their value is determined by Zoetis common stock performance plus a small cash-equivalent component.
FULLER JULIE reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Executive Vice President Julie Fuller received a grant of 314.6453 phantom stock units on July 10, 2026 under the Zoetis Supplemental Savings Plan. These units are cash-settled based on Zoetis common stock value and cash-equivalent investments, bringing her total phantom stock unit holdings to 2112.6819.
Lagano Roxanne reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Roxanne Lagano received a grant of 314.6453 phantom stock units at $26.2200 per unit under the Zoetis Supplemental Savings Plan. These cash-settled units track Zoetis common stock plus cash-equivalent investments and increase her phantom stock unit balance to 30,946.8610.
Zoetis Inc. reported that Executive Vice President Ferran Astorga Jeannette acquired 45.3272 Phantom Stock Units on 2026-07-10 under the Zoetis Supplemental Savings Plan. These units relate to 15.7289 underlying shares of common stock and bring the total phantom stock unit balance to 2296.1569. The units are settled in cash after separation from service, and their value is tied to Zoetis common stock plus cash-equivalent investments, which typically represent around 5% of each unit’s value.